Key Takeaways:
iSpecimen Inc. (NASDAQ: ISPC) will enact a 1-for-40 reverse stock split effective April 27 to regain compliance with Nasdaq listing rules, a move that sent its shares tumbling over 22%.
The split is intended to “increase the per share trading price of the Company's common stock to better attract certain institutional and other investors and comply with the minimum bid price requirement for maintaining the listing,” the company said in a statement.
Effective at 4:30 p.m. ET on April 27, the split will reduce outstanding shares from 52,639,796 to approximately 1,316,032. Trading on a split-adjusted basis will begin on April 28 under the same "ISPC" ticker but with a new CUSIP number of 45032V306. All options, warrants, and restricted stock units will be proportionally adjusted.
This marks iSpecimen’s second reverse split in less than two years, a strategy employed to combat a persistently low stock price. The announcement triggered a 22.19% decline in the stock, a market reaction that mirrors a 23.17% drop seen after the company announced a 1-for-20 reverse split on September 11, 2024. The company has until May 18, 2026, to meet Nasdaq’s $1.00 minimum bid requirement.
The repeated use of reverse splits highlights the company's financial struggles, including an accumulated deficit of $82.4 million as of December 31, 2025. Compounding the pressure, an effective S-3 filing from January 16, 2026, registers 101,000,000 common shares for resale by a preferred stock investor, which the company’s own filing warns could exert downward pressure on the share price.
The negative market reaction suggests investors view the reverse split as a superficial fix, not a solution to the underlying business challenges. With a history of similar actions leading to significant sell-offs, investors will be closely watching whether iSpecimen can achieve compliance by the May deadline or if the stock will face continued pressure.
This article is for informational purposes only and does not constitute investment advice.
